ReviewJournal of pharmaceutical analysis2023

Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection.

Wujun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.